Amedisys (AMED) Tops Q1 EPS by 11c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $100.99 --0%
Financial Fact:
Cost of service, excluding depreciation and amortization: 212.12M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Cost of service, excluding depreciation and amortization: 212.12M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q1 EPS of $1.23, $0.11 better than the analyst estimate of $1.12. Revenue for the quarter came in at $545.3 million versus the consensus estimate of $558.84 million.
GUIDANCE:
Amedisys sees FY2022 EPS of $5.23-$5.45, versus the consensus of $5.33. Amedisys sees FY2022 revenue of $2.33-2.365 billion, versus the consensus of $2.36 billion.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sunrun (RUN) Tops Q3 EPS by 24c
- Evolus (EOLS) Misses Q3 EPS by 13c
- Arcus Biosciences (RCUS) Misses Q3 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
